ArticleFrontiers in neurology2026
Real-world 24-month pain outcomes of disk percutaneous ablation and extraction versus Disc-FX nucleoplasty for lumbar discogenic pain and contained lumbar disk herniation: a single-center retrospective cohort study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Discogenic pain and contained lumbar disk herniation are important causes of chronic low back pain. Current intradiscal minimally invasive techniques have long-term efficacy limitations. Disk percutaneous ablation and extraction (DPAE) lacks systematical long-term outcomes evaluation. This study compared mid-to-long-term clinical outcomes of DPAE and standard Disc-FX in such patients. Methods: This single-center retrospective cohort study included 198 patients: 110 underwent DPAE, 88 received Disc-FX. Primary outcome was the change in low back pain visual analog scale (VAS) score at 24 months. Secondary outcomes included Oswestry Disability Index (ODI), Patient Global Impression of Change (PGIC), achievement of the minimal clinically important difference (MCID), composite treatment success, and reintervention rate. The safety endpoint was perioperative/follow-up complications. Propensity score matching controlled confounding; statistical analyses included analysis of covariance, linear mixed-effects models, logistic regression, and Cox models. Results: At 24 months, DPAE group had a mean VAS reduction of 5.29 ± 2.06 vs. 4.17 ± 2.24 in Disc-FX group ( Discussion: Disk percutaneous ablation and extraction may offer a more durable minimally invasive treatment option. Future multicenter prospective studies are warranted to further validate its long-term efficacy and define its optimal indications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.